Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial

Published:2020-10 Issue:10 Volume:21 Page:1269-1282
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Diéras Véronique,Han Hyo S,Kaufman Bella,Wildiers Hans,Friedlander Michael,Ayoub Jean-Pierre,Puhalla Shannon L,Bondarenko Igor,Campone Mario,Jakobsen Erik H,Jalving Mathilde,Oprean Cristina,Palácová Marketa,Park Yeon Hee,Shparyk Yaroslav,Yañez Eduardo,Khandelwal Nikhil,Kundu Madan G,Dudley Matthew,Ratajczak Christine K,Maag David,Arun Banu K

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years;Malone;Cancer Res,2006

2. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer;Peto;J Natl Cancer Inst,1999

3. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer;Atchley;J Clin Oncol,2008

4. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation;Litton;N Engl J Med,2018

5. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation;Robson;N Engl J Med,2017

Cited by 229 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing;British Journal of Cancer;2024-08-30

2. The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models;Genome Medicine;2024-08-26

3. Neurological toxicities with poly (ADP-ribose) polymerase inhibitors in cancer patients: a systematic review and meta-analysis;Journal of Chemotherapy;2024-08-23

4. Strategies for the prevention or reversal of PARP inhibitor resistance;Expert Review of Anticancer Therapy;2024-08-20

5. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7);The Breast;2024-08